Reports and Data

Anthrax Vaccines Market Growth to Be Worth USD 863.7 Million by 2026 : Reports and Data

The study methodologies used to examine Anthrax Vaccines Market for the forecast period, 2020 - 2026 further classifies the industry by type, geography, end-use and end-user to add more precision and bring to light factors responsible for augmenting business development.

 

New York, NY -- (SBWIRE) -- 04/15/2021 -- The global Anthrax Vaccines Market is expected to reach USD 863.7 million by 2026, according to a new report by Reports and Data. The market is stimulated by increasing prevalence of infectious diseases like anthrax worldwide. Besides, the cost-effectiveness of immunizations, new investments opportunities from government, research foundations, donors, advances in research and manufacturing technologies is anticipated to fuel the market growth in the forecast period. Additionally, the presence of large target population in developing markets is driving the market growth.

Nevertheless, lack of awareness, cost-prohibitive vaccination in under-developed nations, scarcity of availability and affordability, strict regulatory norms are the factors which may hamper the market growth in the upcoming years.

An increase in the eating of undercooked meat from infected with the disease is causative of the growth of the market. Also, an increase in industrial processing of contaminated materials like hides and hair wool among others is expected to support the market growth in the future.

Key participants include Merck & Co. Inc., Emergent Bio-Solutions, Zoetis Inc., PharmaAthene Inc., Biogenesis Bago Inc., Porton Biopharma Inc., Colorado Serum, Merial, Intervac, and Vecol among others.

To Get Sample Copy of Report visit @ https://www.reportsanddata.com/sample-enquiry-form/1357

The markets in the Asia Pacific and Latin America region are projected to witness significant growth in the forecast period. Developing countries like China and India are likely to drive the market demand in the Asia Pacific region in the upcoming years attributed to economic growth, improved health care infrastructure, increase in the number of insurance payers, growth of the private health care sector, and growing awareness for healthy well-being in these nations.

For the purpose of this report, Reports and Data have segmented global anthrax vaccines market on the basis of product type, application, end-user, and region:

Product Type Outlook (Revenue, USD Million; 2016-2026)

Cell-Free PA Vaccines
Anthrax Vaccine Adsorbed (AVA)
Anthrax Vaccine Precipitated (AVP)
Live Cells

Application Outlook (Revenue, USD Million; 2016-2026)

Human Use
Animal Use

End-user Outlook (Revenue, USD Million; 2016-2026)

Hospitals
Clinics
Vaccination Centers
Others

Regional Outlook (Revenue, USD Million; 2016-2026)

North America
Europe
Asia Pacific
Latin America
MEA

To get a Discount on the Anthrax Vaccines Market Report, Click @ https://www.reportsanddata.com/discount-enquiry-form/1357

Further key findings from the report suggest

Cell-Free PA vaccines contributed to the largest market share with around 60% of the market share in 2018 and are expected to witness a growth rate of 7.6% during the forecast period. In comparison to AVA, the British AVP consists of lower levels of PA and higher concentrations of additional Bacillus anthracis antigens, including edema factor (EF), lethal factor (LF), and specific bacillus surface proteins. These enhanced components in the British AVP anthrax vaccines may provide a slight improvement in protection against anthrax.

Anthrax vaccines are primarily used for providing vaccination to animals. Application of these vaccines for animal use dominated the market with a market share of more than 90% in 2018 and is expected to grow at a CAGR of 7.3% in the period 2019-2026.

The market in North America held the largest market share in 2018 and is estimated to have a CAGR of 7.1% during the forecast period.

In July 2018, the advisory committee on Immunization Practices chose to approve recommendations for the usage of Anthrax Vaccine Adsorbed (AVA) in post-exposure prophylaxis (PEP) in the occurrence of a widespread release of Bacillus anthracis spores.

Browse Full Report @ https://www.reportsanddata.com/report-detail/anthrax-vaccines-market#table-of-contents

Table of Content:

Chapter 1. Market Synopsis
1.1. Market Definition
1.2. Research Scope & Premise
1.3. Methodology
1.4. Market Estimation Technique
Chapter 2. Executive Summary
2.1. Summary Snapshot, 2016-2026
Chapter 3. Indicative Metrics
Chapter 4. Anthrax Vaccines Segmentation & Impact Analysis
4.1. Anthrax Vaccines Material Segmentation Analysis
4.2. Industrial Outlook
4.2.1. Market indicators analysis
4.2.2. Market drivers analysis
4.2.2.1. Rising prevalence of Anthrax
4.2.2.2. Increased eating of undercooked or raw meat from infected animals
4.2.2.3. Increase in industrial processing of contaminated materials
4.2.3. Market restraints analysis
4.2.3.1. Lack of awareness
4.3. Technological Insights
4.4. Regulatory Framework
4.5. ETOP Analysis

Continued…

Request customization of the report @ https://www.reportsanddata.com/request-customization-form/1357

Thank you for reading our report. To receive further information on the report or to enquire about its customization, please get in touch with us and get your report tailored according to your needs.

About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

Contact Us:
John W
Head of Business Development
40 Wall St. 28th floor New York City
NY 10005 United States
Direct Line: +1-212-710-1370